Inpharmation takes an evidence-based approach to international reference pricing (IRP) forecasts, this means all our services:
- Capture the full complexity of the reference pricing system.
- Communicate forecast drivers using clear and simple rules, not vague assumptions.
- Are engineered for efficiency and stability.
The world’s leading pharma companies work with Inpharmation when they need international pricing forecasts built upon a solid evidence-base, including:
- International reference pricing rules database with full global coverage.
- The industry-leading strategic IRP strategy simulator.
- The industry-leading launch optimization engine.
Inpharmation’s international reference pricing simulators have been developed over two decades specifically for the strategic analysis requirements of global pharma pricing and market access teams. Because 7 of the top-10 countries, ranked by pharmaceutical sales, use IRP as part of the pricing and reimbursement agreement process, no pricing strategy can ignore the impact of reference pricing.
"Europe's most respected pharma forecasting & pricing specialist consultancy."
Centre for Executive Leadership
What can evidence-based international reference pricing do for you?
Inpharmation has spent decades modelling the growth of the international reference pricing system (sometimes known as the external reference pricing or international price referencing system).
If you are currently modelling the international reference pricing system you will understand the frustration of trying to capture the many different complex elements. Inpharmation’s evidence-based international reference pricing database encompasses a reference pricing system of over 90 countries and 33 different reference pricing methodologies.
All our clients benefit from pricing solutions based on extensively validated models and methodologies.
Inpharmation has approaches for each stage of your pharmaceutical product’s lifecycle. Inpharmation is expert in behavior-based pricing and econometric pricing models for early stage assets, payer summit, payer conjoint and probabilistic van Westendorp for products coming to market. We also have international system models and price-demand elasticity models for products near or past launch.
Inpharmation runs Europe’s leading pharmaceutical pricing for market access executive training courses. In all our projects we place great importance on transferring knowledge and skills to our clients.
The evidence behind Inpharmation’s fact-based approach to pricing is meticulously documented in the book Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals by Inpharmation’s Managing Director, Gary Johnson.